• Websitewww.ikenaoncology.com
  • Est. Since2016-01-01
  • InvestorsAtlas Venture

About Ikena Oncology

Kyn Therapeutics is developing a novel approach to target both IDO and TDO mediated immunosuppression through enzymatic degradation of kynurenine systemically and in the tumor microenvironment. Inhibiting the IDO/TDO pathway is expected to have broad application across many tumor types.

Jobs From Ikena Oncology

Director, Computational Biology

Ikena Oncology - Boston, MA, US

Program Manager

Ikena Oncology - Boston, MA, US

Senior Director, Translational Research

Ikena Oncology - Boston, MA, US

Senior Clinical Scientist

Ikena Oncology - Boston, MA, US

Senior Scientist, Cancer Biology

Ikena Oncology - Boston, MA, US

Principal Research Associate, In Vivo Pharmacology

Ikena Oncology - Boston, MA, US

Clinical Research Associate

Ikena Oncology - Boston, MA, US

Senior Scientist, Analytical Sciences

Ikena Oncology - Boston, MA, US

Scientist I

Ikena Oncology - Boston, MA, US

Director, Human Resources

Ikena Oncology - Boston, MA, US

Scientist II, Discovery Toxicology

Ikena Oncology - Boston, MA, US